Avoiding an unpleasant trade-off Right now, older adults face an unpleasant trade-off: lose weight and improve your cardiovascular health, but perhaps accelerate your decline
doi: 10.1210/clinem/dgaa327 [DOI] [PMC free article] [PubMed] [Google Scholar] 49.Christensen MB, Calanna S, Holst JJ, et al
This will allow people who took Ozempic and developed NAION to join together in litigation against Novo Nordisk and other GLP-1 manufacturers
It is important to note that: Most clinical trials have follow-up periods of 25 years, which may not capture very long-term cancer development Patients with type 2 diabetes and obesity have baseline elevated cancer risks due to metabolic factors Post-marketing surveillance continues to monitor for rare or delayed adverse events The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) continue to review safety data as part of ongoing pharmacovigilance activities, and no major cancer-related safety signals have emerged that would warrant withdrawal or significant restriction of these medicines
GIP immunoreactivity was further observed in the olfactory bulb, basal ganglia (including the striatum, nucleus accumbens, ventral pallidum and SN), amygdala, lateral septal nucleus as well as multiple hypothalamic nuclei
